The prevalence of obesity and PCOS was highest in women using GLP-1 receptor agonists; chronic hypertension, cardiovascular disease, and use of antihypertensive and lipid-modifying agents were highest in SGLT2 inhibitor users. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.